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G0S2 regulates innate immunity of Kawasaki disease via lncRNA RP1-28O 10.1 
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Summary of manuscript 
Kawasaki disease (KD) is a systemic vasculitis that is the most common cause of 
acquired heart disease in children. However, the etiology of KD remains unknown. Long-
cording RNAs (lncRNA) contribute to the pathophysiology of various diseases, including 
myocardial infraction and cardiomyopathy. There have been few studies reporting a role 
for lncRNAs in KD-associated inflammation and we conducted this study to investigate 
whether there is a role for lncRNAs. 
We enrolled 50 patients with KD and 45 controls. lncRNA expression in monocytes 
were determined by Cap analysis gene expression sequencing (CAGE-seq) and validated 
by quantitative real-time PCR. Differentially-expressed lncRNAs were further 
investigated to determine whether they were directly regulated by immune responses. 
Twenty-one candidate lncRNA transcripts were identified by CAGE-seq as being 
differentially expressed during the acute phase of KD. Of the twenty-one lncRNAs, the 
expression level of RP1-28O10.1 was up-regulated and rapidly decreased in acute phase 
of KD, confirming that the expression level of RP1-28O10.1 was regulated by TLR ligand. 
Moreover, G0S2 was co-expressed with RP1-28O10.1 and G0S2 regulated inflammatory 
cytokines via RP1-28O 10.1. 
We demonstrated that RP1-28O 10.1 and G0S2 interact with each other and play a 
pivotal role of innate immunity and inflammation during acute stage of KD. 
 
